The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models

Antibody-drug conjugates (ADC) are a novel way to deliver potent cytotoxic compounds to cells expressing a specific antigen. Four ADC targeting CD19, including SAR3419 (coltuximab ravtansine), have entered clinical development. Here, we present huB4-DGN462, a novel ADC based on the SAR3419 anti-CD19...

Descripción completa

Detalles Bibliográficos
Autores principales: Hicks, Stuart W., Tarantelli, Chiara, Wilhem, Alan, Gaudio, Eugenio, Li, Min, Arribas, Alberto J., Spriano, Filippo, Bordone, Roberta, Cascione, Luciano, Lai, Katharine C., Qiu, Qifeng, Taborelli, Monica, Rossi, Davide, Stussi, Georg, Zucca, Emanuele, Stathis, Anastasios, Sloss, Callum M., Bertoni, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669148/
https://www.ncbi.nlm.nih.gov/pubmed/30733273
http://dx.doi.org/10.3324/haematol.2018.211011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669148/
https://www.ncbi.nlm.nih.gov/pubmed/30733273
http://dx.doi.org/10.3324/haematol.2018.211011

Ejemplares similares